Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective
出版年份 2013 全文链接
标题
Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective
作者
关键词
Orlistat, Cholesteryl Ester Transfer Protein, Cholesterol Efflux, Torcetrapib, Cholesteryl Ester Transfer Protein Activity
出版物
CLINICAL PHARMACOKINETICS
Volume 52, Issue 8, Pages 615-626
出版商
Springer Nature
发表日期
2013-05-08
DOI
10.1007/s40262-013-0071-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects
- (2013) Michael Derks et al. CLINICAL DRUG INVESTIGATION
- In vivo evaluation of drug-drug interactions linked to UGT inhibition: the effect of probenecid on dalcetrapib pharmacokinetics
- (2013) Pau Aceves Baldó et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs
- (2012) Da Xiao et al. BIOCHEMICAL PHARMACOLOGY
- Design, synthesis and structure–activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors
- (2012) Maria-Carmen Fernandez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
- (2012) Rajesh Krishna et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Rationale for cholesteryl ester transfer protein inhibition
- (2012) Bernd Hewing et al. CURRENT OPINION IN LIPIDOLOGY
- Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial
- (2012) Thomas F. Lüscher et al. EUROPEAN HEART JOURNAL
- A Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans
- (2012) Troy C. Sarich et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- No clinically relevant drug–drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30)
- (2012) Annie Young et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Evidence of a Drug–Drug Interaction Linked to Inhibition of Ester Hydrolysis by Orlistat
- (2012) Darren Bentley et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
- (2012) Philip J. Barter et al. JOURNAL OF LIPID RESEARCH
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
- (2012) Benjamin F Voight et al. LANCET
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects
- (2011) Rajesh Krishna et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling
- (2011) Olaf Weber et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Characterization of antioxidant/anti-inflammatory properties and apoA-I-containing subpopulations of HDL from family subjects with monogenic low HDL disorders
- (2011) Georgios Daniil et al. CLINICA CHIMICA ACTA
- Effects of Food Intake on the Pharmacokinetic Properties of Dalcetrapib: Findings From Three Phase I, Single-Dose Crossover Studies in Healthy Volunteers
- (2011) Michael Derks et al. CLINICAL THERAPEUTICS
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol
- (2011) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure
- (2011) Guoqing Cao et al. JOURNAL OF LIPID RESEARCH
- Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
- (2011) Ronald M. Krauss et al. JOURNAL OF LIPID RESEARCH
- Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
- (2011) Zahi A Fayad et al. LANCET
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
- (2011) Amit V. Khera et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey
- (2011) Olaf Kuhlmann et al. XENOBIOTICA
- Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib
- (2010) Laurent Yvan-Charvet et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe
- (2010) Michael Derks et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin
- (2010) Michael Derks et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drug-Drug Interactions
- (2010) Michael Derks et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
- (2010) Eric J. Niesor et al. JOURNAL OF LIPID RESEARCH
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
- (2010) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Pharmacology and Off-Target Effects of Some Cholesterol Ester Transfer Protein Inhibitors
- (2009) Menno Vergeer et al. AMERICAN JOURNAL OF CARDIOLOGY
- Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
- (2009) Eric Bruckert et al. ATHEROSCLEROSIS
- Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
- (2009) Rajesh Krishna et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
- (2009) Rajesh Krishna et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans
- (2009) Laura Calabresi et al. CIRCULATION
- Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction
- (2009) Paul M. Ridker et al. Circulation-Cardiovascular Genetics
- Pharmacokinetic, Pharmacodynamic, and Safety Profile of a New Cholesteryl Ester Transfer Protein Inhibitor in Healthy Human Subjects
- (2009) R Wolk et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics, Metabolism, and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Rats and Rhesus Monkeys
- (2009) E. Y. Tan et al. DRUG METABOLISM AND DISPOSITION
- Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans
- (2009) S. Kumar et al. DRUG METABOLISM AND DISPOSITION
- Macrophage cholesterol efflux correlates with lipoprotein subclass distribution and risk of obstructive coronary artery disease in patients undergoing coronary angiography
- (2009) Patrick Linsel-Nitschke et al. Lipids in Health and Disease
- Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects
- (2008) R Krishna et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Metabolism, Pharmacokinetics, and Excretion of a Cholesteryl Ester Transfer Protein Inhibitor, Torcetrapib, in Rats, Monkeys, and Mice: Characterization of Unusual and Novel Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and 1H Nuclear Magnetic Resonance
- (2008) C. Prakash et al. DRUG METABOLISM AND DISPOSITION
- Pharmacokinetics, Metabolism, and Excretion of Torcetrapib, a Cholesteryl Ester Transfer Protein Inhibitor, in Humans
- (2008) D. Dalvie et al. DRUG METABOLISM AND DISPOSITION
- Association of Loss-of-Function Mutations in the ABCA1 Gene With High-Density Lipoprotein Cholesterol Levels and Risk of Ischemic Heart Disease
- (2008) Ruth Frikke-Schmidt JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity With Systemic Oxidative Stress and Cardiovascular Risk
- (2008) Tamali Bhattacharyya JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
- (2008) Alexander Thompson JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Assessment of the CYP3A-Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers
- (2008) Rajesh Krishna et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins
- (2008) A. R. Tall JOURNAL OF INTERNAL MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started